Results 161 to 170 of about 4,279 (197)
Some of the next articles are maybe not open access.
Drugs, 2008
Dalbavancin is a semisynthetic glycopeptide antibacterial agent that is active against Gram-positive bacteria associated with complicated skin and skin structure infections (cSSSIs). It is administered as a two-dose regimen intravenously infused over 30 minutes once weekly.
Vanessa R, Anderson, Gillian M, Keating
+7 more sources
Dalbavancin is a semisynthetic glycopeptide antibacterial agent that is active against Gram-positive bacteria associated with complicated skin and skin structure infections (cSSSIs). It is administered as a two-dose regimen intravenously infused over 30 minutes once weekly.
Vanessa R, Anderson, Gillian M, Keating
+7 more sources
Canadian Journal of Health Technologies, 2022
CADTH recommends that Xydalba should be reimbursed by public drug plans for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA), only if certain conditions are met. Xydalba should only be covered to treat patients who have
openaire +1 more source
CADTH recommends that Xydalba should be reimbursed by public drug plans for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA), only if certain conditions are met. Xydalba should only be covered to treat patients who have
openaire +1 more source
Drugs of Today, 2007
Dalbavancin is a second-generation lipoglycopeptide bactericidal agent. Due to its once-weekly intravenous (i.v.) dosing and greater tissue penetration, dalbavancin may offer advantages in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) as compared to vancomycin, the gold standard in the treatment of MRSA.
openaire +2 more sources
Dalbavancin is a second-generation lipoglycopeptide bactericidal agent. Due to its once-weekly intravenous (i.v.) dosing and greater tissue penetration, dalbavancin may offer advantages in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) as compared to vancomycin, the gold standard in the treatment of MRSA.
openaire +2 more sources
Dalbavancin: an investigational glycopeptide
Expert Review of Anti-infective Therapy, 2004Glycopeptide antimicrobials have been a component of our therapeutic armamentarium for nearly 50 years. Although vancomycin, and more recently teicoplanin, have performed yeoman service over the years, the specter of bacterial resistance among Gram-positive aerobes has created doubts concerning how long they will continue to be useful antimicrobial ...
openaire +2 more sources